No prospective randomized head-to-head trial of anti-TNF vs. anti-integrin agents in IBD have been published, except for the VARSITY study18 in which VDZ and ADA were compared in a phase 3b, randomized, double-blind trial enrolling subjects with moderate-to-severe UC. The gene discussed is TNF; the disease is inflammatory bowel disease.